How to Help Your Patients Find Igalmi in Stock: A Provider's Guide

How to Help Your Patients Find Igalmi in Stock: A Provider's Guide

As a healthcare provider treating acute agitation, you know that medication access can be just as important as the clinical decision itself. Igalmi (Dexmedetomidine sublingual film) offers a non-injectable option for managing agitation in schizophrenia and bipolar disorder — but finding it in stock can be a challenge.

This guide outlines practical steps you can take to help your patients access Igalmi in 2026.

Current Availability of Igalmi

Igalmi is not in an FDA-listed shortage as of 2026, but real-world availability is limited by several factors:

• Single manufacturer: BioXcel Therapeutics is the sole producer
• No generic version: No alternative suppliers for the sublingual film formulation
• Hospital-centric distribution: Primarily stocked at psychiatric inpatient facilities and larger emergency departments
• Formulary gaps: Many facilities haven't added Igalmi to their formulary
• Cost: Approximately $95-$105 per film, which can affect facility purchasing decisions

Why Patients Can't Find Igalmi

Understanding the barriers your patients face helps you address them more effectively:

It's Not a Retail Pharmacy Product

Unlike medications patients fill at their local pharmacy, Igalmi requires healthcare provider supervision for administration. Patients can't walk into a Walgreens or CVS and pick it up. This creates a fundamental access gap — patients need to find a facility that stocks it, not just a pharmacy.

Limited Formulary Adoption

Many hospital P&T committees have been slow to add Igalmi. Facilities with established agitation protocols using Haloperidol, Olanzapine, or Lorazepam may see Igalmi as an incremental addition rather than a necessity, especially given its cost.

Geographic Disparities

Larger academic medical centers and urban psychiatric facilities are more likely to stock Igalmi than rural hospitals or community mental health centers. This creates geographic access disparities that disproportionately affect patients in underserved areas.

What Providers Can Do: 5 Actionable Steps

Step 1: Use Medfinder for Providers

Medfinder.com/providers is designed specifically for healthcare professionals looking to locate hard-to-find medications. You can:

• Search for facilities with Igalmi in stock near your location
• Verify availability before initiating a patient transfer or referral
• Save time that would otherwise be spent on phone calls to multiple pharmacies

Step 2: Contact BioXcel Therapeutics Directly

The manufacturer offers dedicated support for providers:

• Medical information line: 1-833-201-1088
• Email: medinfo@bioxceltherapeutics.com
• Website: igalmi.com

They can help identify distributors and facilities with current stock, and may provide clinical education materials for your team.

Step 3: Advocate for Formulary Inclusion

If your facility doesn't carry Igalmi, consider presenting a case to your P&T committee. Key talking points include:

• Non-injectable option reduces needle-related injuries and confrontation during agitation episodes
• Alpha-2 agonist mechanism provides cooperative sedation without respiratory depression
• Potential to reduce use of physical restraints
• Not a controlled substance — simplifies storage and dispensing logistics
• Phase III SERENITY trial data showing statistically significant reduction in agitation scores

Step 4: Establish Relationships With Stocking Facilities

Build referral relationships with nearby facilities that carry Igalmi. In acute agitation situations, having a pre-established pathway for patient transfer or medication access can be critical. Consider:

• Identifying the nearest 2-3 facilities that stock Igalmi
• Establishing transfer protocols for patients who would benefit from Igalmi
• Creating mutual aid agreements with neighboring facilities for medication sharing

Step 5: Educate Your Clinical Team

Ensure your nursing staff, emergency medicine colleagues, and psychiatric team members are familiar with:

• Igalmi's indications, dosing, and administration technique
• The sublingual and buccal placement options
• Vital sign monitoring requirements (BP, HR, orthostatic measurements)
• The 8-hour activity restriction post-administration
• When to use alternatives if Igalmi is unavailable

Alternatives When Igalmi Is Unavailable

When Igalmi can't be obtained, maintain evidence-based agitation protocols using:

• Haloperidol (Haldol) 5-10 mg IM ± Lorazepam 2 mg IM ± Diphenhydramine 50 mg IM
• Olanzapine (Zyprexa) 10 mg IM — do not combine with benzodiazepines
• Ziprasidone (Geodon) 10-20 mg IM — monitor QT interval
• Lorazepam (Ativan) 2 mg IM/IV — effective for non-specific agitation

For a detailed clinical comparison, see our article on alternatives to Igalmi.

Workflow Tips for Your Clinical Team

Integrate Igalmi access into your existing workflows:

• Add a pharmacy check to your agitation protocol: Before defaulting to IM medications, check if Igalmi is available in your facility's pharmacy
• Create a quick-reference card: Include Igalmi dosing (120 mcg mild/moderate, 180 mcg severe), monitoring schedule, and administration technique for nursing staff
• Bookmark Medfinder: Add medfinder.com/providers to your workstation for quick access when you need to locate Igalmi externally
• Document access barriers: Track instances where Igalmi was clinically indicated but unavailable — this data supports future formulary requests and demonstrates unmet need
• Patient education: When patients are stabilized and ready for discharge, provide information about Igalmi and what to expect if they need it again in the future

Final Thoughts

Igalmi fills an important gap in the acute agitation treatment toolkit, but access barriers remain a practical challenge in 2026. By leveraging tools like Medfinder for Providers, advocating for formulary inclusion, and maintaining robust alternative protocols, you can ensure your patients receive the best possible care regardless of Igalmi's availability at your specific facility.

Related provider resources:

• Igalmi shortage: what providers need to know
• How to help patients save money on Igalmi
• Igalmi drug interactions
• How does Igalmi work?